Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials

ABSTRACT: Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials

PROVIDER: PRJNA926693 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR23196184_1.fastq.gz	Fastqsanger.gz
	SRR23196184_2.fastq.gz	Fastqsanger.gz
	SRR23196185_1.fastq.gz	Fastqsanger.gz
	SRR23196185_2.fastq.gz	Fastqsanger.gz
	SRR23196186_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials

Project description:We established patient-derived organoids and monolayer culture cells from the salivary gland cancer cases. To compare the RNA profiles of primary culture cells (Organoids and monolayer culture cells) and their parental tumors, we isolated total RNA from 2 cases of the salivary gland cancer and performed transcriptome sequencing for the organoids, monolayer culture cells, and their parental tumors of both cases. Case 6 is a case of adenoid cystic carcinoma and Case 11 is a case of salivary duct carcinoma.

2023-04-27 | GSE223554 | GEO

Salivary gland cancer organoids are valid for preclinical genotype-oriented medical precision trials.

Project description:Salivary gland cancers (SGCs) are heterogeneous tumors, and precision oncology represents a promising therapeutic approach; however, its impact on SGCs remains obscure. This study aimed to establish a translational model for testing molecular-targeted therapies by combining patient-derived organoids and genomic analyses of SGCs. We enrolled 29 patients, including 24 with SGCs and 5 with benign tumors. Resected tumors were subjected to organoid and monolayer cultures, as well as whole-exome sequencing. Organoid and monolayer cultures of SGCs were successfully established in 70.8% and 62.5% of cases, respectively. Organoids retained most histopathological and genetic profiles of their original tumors. In contrast, 40% of the monolayer-cultured cells did not harbor somatic mutations of their original tumors. The efficacy of molecular-targeted drugs tested on organoids depended on their oncogenic features. Organoids recapitulated the primary tumors and were useful for testing genotype-oriented molecular targeted therapy, which is valuable for precision medicine in patients with SGCs.

| S-EPMC10189274 | biostudies-literature

medical waste metagenome

Project description:medical waste metagenome

| PRJNA1138881 | ENA

Listeria monocytogenes strain:medical patient | isolate:medical patient

Project description:Listeria monocytogenes strain:medical patient | isolate:medical patient Genome sequencing

| PRJNA814010 | ENA

A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials

Project description:A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials

| PRJNA450984 | ENA

A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials [microarray]

Project description:A Syngeneic ErbB2 Mammary Cancer Model for Preclinical Immunotherapy Trials [microarray]